Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia: Cost Effectiveness and Risk Sharing

Author： Wlodarczyk John H.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.24, Iss.9, 2006-01, pp. : 903-915

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence

By Provencher Steeve   Sitbon Olivier   Simonneau Gérald  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 8, 2005-07 ,pp. : 1337-1348

Informa Healthcare

Access to resources Recommend Favorite

Cost Effectiveness of Zanamivir for the Treatment of Influenza in a High Risk Population in Australia

By Mauskopf J.A.  

PharmacoEconomics, Vol. 17, Iss. 6, 2000-06 ,pp. : 611-620

Adis International

Access to resources Recommend Favorite

Bosentan effective in severe pulmonary hypertension

By  

Inpharma, Vol. 1, Iss. 1331, 2002-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Sitaxsentan sodium appears to be more cost effective than bosentan in treating patients with pulmonary arterial hypertension (PAH)

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 508, 2006-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Bosentan improves exercise capacity in pulmonary hypertension

By  

Inpharma, Vol. 1, Iss. 1309, 2001-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite